Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00471237 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study Evaluating SB-751689 in Post-Menopausal Women With Osteoporosis.
A Phase 2 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 2
- Development phase
- 564
- Enrollment target
NCT00471237 is a Phase 2 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 564 participants.
The verdict
NCT00471237, a Phase 2 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 564 participants
- Enrollment target
Study Summary
This is a 12 month study designed to evaluate the safety and effectiveness of SB-751689 in the treatment of osteoporosis in post-menopausal women, in comparison with 2 active comparators and placebo.
Interventions
- DRUG Teriparatide
- DRUG Alendronate
- DRUG Ronacaleret
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 564 participants |
| Start Date | 2007-05-14 |
| Est. Completion | 2008-12-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00471237
The ClinicalTrials.gov registry entry for NCT00471237 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 564 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Teriparatide is the first listed.
NCT00471237 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00471237 about?
NCT00471237 is a clinical study titled "A Phase II Study Evaluating SB-751689 in Post-Menopausal Women With Osteoporosis.". This is a 12 month study designed to evaluate the safety and effectiveness of SB-751689 in the treatment of osteoporosis in post-menopausal women, in comparison with 2 active comparators and placebo.
What is the current status of trial NCT00471237?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 564 participants. The study started on 2007-05-14. Estimated completion is 2008-12-26.
What interventions are being tested in trial NCT00471237?
The interventions under investigation include: Teriparatide (DRUG), Alendronate (DRUG), Ronacaleret (DRUG).
Who is sponsoring clinical trial NCT00471237?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.